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Abstract: Alzheimer disease (AD) is the most common progressive neurodegenerative disorder causing increased morbidity and
mortality. It is characterized by accumulation of amyloid-β in neurons. As there is no known definitive treatment of this disorder,
studies trying to determine its exact pathogenetic pathways and target therapies for these specific pathways are being rapidly conducted.
Autophagy is one of the areas of interest in studies on the pathogenesis of AD. It is a process of self-digestion that is thought to be a
response to stressors and allows cells to adapt to environmental changes. There is accumulating evidence showing an association between
autophagy and some disorders like cancer, infectious disease, and, in particular, neurodegenerative disorders. Growing attention has
been focused on impaired autophagy in neurodegenerative disorders including AD, resulting in buildup of toxic molecules because of
inappropriate activation of proteases or defective proteolysis. The question of whether autophagic response may be precisely modulated
to prevent or treat neurodegenerative disorders like AD is still unanswered. In the future, it is thought that the autophagic process may
be the one of the cornerstones of the treatment of AD. In this review, we summarize the knowledge of autophagy in the pathogenesis of
AD in light of the current literature.
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1. Introduction
Alzheimer disease (AD) is mainly characterized by
progressive degeneration of the brain cells and leads
to irreversible decline in cognitive abilities. The major
pathological factor of this disorder is accumulation of
amyloid-β (Aβ) protein in the cortex and hippocampal
area, resulting in cognitive impairment and memory loss.
Researches on therapeutic strategies for AD have mainly
focused on anti-Aβ strategies, but most recently, studies
examining the effect of monoclonal antibodies against
Aβ protein such as solanezumab and bapineuzumab
have resulted in disappointment due to high toxicity or
ineffectiveness (1,2).
Autophagy is thought to be one of the cleaving
systems clearing toxic Aβ proteins from neurons. This
pathway sustains cell life by protecting cells against
deprivation and other threatening stressors (3). Another
hallmark pathological process in AD is accumulation of
hyperphosphorylated tau protein in the brain, resulting
in neurofibrillary tangles. Autophagy is an inhibitor of
the mammalian target of rapamycin (mTOR) induction
pathway, which has been shown to be a promoter of
hyperphosphorylation and accumulation of tau proteins (4).
There is growing clinical and preclinical evidence
about association of autophagy and AD in the literature,
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but none of these studies have succeeded in showing a
link between autophagy and modulation of the disease
progression yet (5). In this review, the importance of
autophagy in AD pathogenesis will be discussed in light of
the current knowledge in the literature.
2. Definition and mechanisms of autophagy
Autophagy is a process of self-digestion. It is thought to
be a response to stressors and it allows cells to adapt to
environmental changes (6). Deprivations in cell conditions
may cause induction of autophagy to provide energy for
the synthesis of essential substrates that are important for
survival of organelles and cells (7). Since de Duve first
described autophagy in 1963, our knowledge about this
issue has continued to grow, especially in the last decade
(6). Today it is thought that there is an association between
autophagy and some disorders like cancer, infectious
disease, and neurodegenerative disorders (8).
Sequestration in the autophagy process first begins
with the formation of a phagophore (Figure) (9). It then
expands into a double-membrane autophagosome and
surrounds a portion of the cytoplasm (6). Endosome, the
product of endocytosis, fuses with the autophagosome,
and this new product is called an amphisome (6). The
autophagosome or amphisome fuses with a lysosome
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Figure. Summary of the autophagic pathway. A double-membrane
phagophore sequesters the assembly of lipids and proteins from
the cytosol as cargo. This autophagosome encounters and fuses
with a lysosome, and finally luminal hydrolases degrade the
cargo. In the autolysosome, macromolecules are digested and the
products are used in the cell through recycling in the cytosol.

(which supplies acid hydrolases), resulting in an
autolysosome (6). In the autolysosome, macromolecules
are digested and the products are used in the cell through
recycling in the cytosol (6,9).
There are three types of autophagic pathways:
macroautophagy, microautophagy, and chaperonemediated autophagy (CMA) (10).
Macroautophagy is the classical and main autophagic
pathway in mammalian cells. Autophagic gene (Atg)
proteins play a major role here. A double-membrane
phagophore sequesters the assembly of lipids and proteins
from the cytosol as cargo (10). This autophagosome
encounters and fuses with a lysosome, and finally luminal
hydrolases degrade the cargo (10–12). If the cargo is
assembled in a particular area of the cell, this autophagy
is accordingly called mitophagy (in mitochondria),
lipophagy (in lipid droplets), ribophagy (in ribosomes),
etc. (10).
Microautophagy is generally seen in yeasts. Cargo
sequestration plays an important role here, too, but the
difference from macroautophagy is that vesicles come from
invagination of the limiting membrane of the vacuole in
yeast and late endosomes in endosomal microautophagy
(10). Autophagosomes occur after these vesicles fuse with
lysosomes (10,13,14).
In CMA, selective cytosolic proteins, chaperones, bind
the client proteins in cytosol and carry these proteins to
the lysosomes (10). For example, if a protein is bound to
the lysosomal membrane protein (LAMP), this protein
reaches the lysosomal lumen through this chaperon

complex (10,15). The first step of CMA is the recognition of
substrate proteins by hsc70/co-chaperones (10). After that,
a substrate–chaperon complex binds to LAMP-2A, and
then the substrate unfolds and translocates into lysosomes
(10,15). Subsequent degradation occurs and finally LAMP2A disassembles into the lysosomal membrane (15).
These three autophagic pathways are regulated by some
hormonal and enzymatic mechanisms. The regulation of
autophagy is extremely complex and not very well known
yet. Nevertheless, some inhibiting and stimulating factors
have been shown in the regulation of autophagic process.
The first described regulator of autophagy is the target
of rapamycin (TOR). Inhibition of TOR with rapamycin is
shown to induce autophagy (16,17). The major inhibitors of
autophagy are 3-methyladenine (3-MA) and wortmannin
(Wm) (16,18). They inhibit phosphatidylinositol-3kinases (PI3K), which are needed for autophagy process
(16). Beclin-1, Atg4, c-Jun N-terminal kinase (JNK), and
reactive oxygen species also have some roles in regulation
of autophagy (16,19). BECN1 is expressed to promote the
synthesis of beclin-1, which has a key role in autophagy
in neurons and glia in human and mouse brains (20). It
regulates the autophagic activity and is essential for the
development of autophagosomes (20). Deficiency of
beclin-1 may promote neurodegeneration and accelerate
Aβ accumulation. The proteins and enzymes associated
with autophagy are regulated by autophagy-related genes.
There are more than 30 types of identified autophagyrelated genes in the literature (21).
3. Role of autophagy in the pathogenesis of
neurodegenerative disorders
Growing attention has been focused on impaired
autophagy in neurodegenerative disorders causing
buildup of toxic molecules in neurons due to inappropriate
activation of proteases or defective proteolysis. Although it
is clear that the autophagy pathway might be involved in
the pathogenesis of neurodegenerative diseases, it is not
certain yet whether it has a causative role or a protective
role, or if it a consequence of the disease process (22).
Cytoplasmic, extracellular, and nuclear inclusions and
aggregation of proteins are the cornerstones of pathogenesis
of neurodegenerative disorders including not only AD but
also Parkinson disease (PD), amyotrophic lateral sclerosis
(ALS), and Huntington disease (HD). These aggregates
cause neuronal damage and synaptic dysfunction. The main
therapeutic approach in the treatment of these disorders is
thought to be related to clearance of these proteins from
the cell. One of the cleaving systems of these particles from
the cell is autophagy. An impairment of macroautophagy,
which inhibits the turnover of free radicals of oxidized
membranes and proteins and of damaged mitochondria, is
likely to speed up neuronal degeneration (23).
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There are some signaling and modulating factors of
autophagy shown to have an impact in the pathogenesis of
neurodegenerative disorders. The major signaling factors
of autophagy are beclin-1, mTOR, LC3 (light chain 3),
p62/sequestosome 1, dynein, parkin, and PINK1 (24).
The main modulating factors are rapamycin, glucose
transporter, small molecular enhancers, lithium, sodium
valproate, clonidine, and carbamazepine (24).
Beclin-1 is shown to participate in the formation of
autophagosomes. In the postmortem analysis of brain cells
of patients with AD, reduced beclin-1 expression is detected
(20). Transgenic AD mice with beclin-1 deficiency are
prone to develop early Aβ accumulation, which seems to
be closely related with reduced autophagy (20). PINK1, a
serine threonine kinase, is a signaling factor for mitophagy
and loss of PINK1 function is shown to be related with
autosomal recessive PD (25). Conversion of LC3-I to LC3II is important for the development of autophagosome
formation, and in symptomatic amyotrophic lateral
sclerosis mice models, it was found that there was an
increased level of LC3-II (26). Mutation of dynein, which
has a role in fusion of autophagosomes and lysosomes, is
shown to participate in familial ALS pathogenesis (27).
Numerous studies also suggested that mTOR-dependent
autophagy can provide neuroprotection in HD (24).
Synuclein, a major constituent of Lewy bodies, is found
to play a role in PD pathogenesis. Macroautophagy and
CMA degrade synuclein and this relationship is evidence
that autophagy has a critical role in PD progression (24,28).
One of the well-known pathogenic mechanisms
in PD is mitochondrial dysfunction (29). Impaired
mitochondrial content of toxic reactive oxygen species
may cause damage to neurons and it has been shown
that mitophagy eliminates these defective mitochondria
and protects the neurons from their negative effects (30).
Parkin and PINK1 mutation are shown to be related to the
development of autosomal recessive PD due to mitophagy
dysfunction and consequent mitochondrial damage (31).
The major pathogenic event in HD is accumulation of
some oligomeric and monomeric aggregates in the neurons.
The triggering factor for this aggregation is mutation in Htt
(32). Studies indicate that sequestration of mTOR leads to
elimination of these aggregates from neurons, and some
modifiers of autophagy have also been shown to improve
neuron survival in various animal models (24,33). This
evidence shows the benefit of autophagy process in HD
pathogenesis.
ALS causes respiratory failure and mortality as a result
of neuronal degeneration and motor neuron loss. In ALS
patients, some abnormalities in autophagy have been
shown (34). Defective autophagy leads to accumulation of
proteins in neurons. The main pathological factor causing
defective autophagy in ALS is increased clearance of
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mutant superoxide dismutase 1 (SOD1) from the neurons
by heat shock protein (HSPB8), which is a strong promoter
of autophagy (26,35).
4. Role of autophagy in the pathogenesis of AD
AD is the most common neurodegenerative disorder in the
elderly and is characterized by accumulation of Aβ proteins
in the neurons. Normally, there is no accumulation of Aβ
proteins in the human central nervous system, because the
rate of clearance is higher than the production rate, at 8.3%
per hour and 7.6% per hour, respectively (36).
There are two pathognomonic findings in the
pathological examination of the brain in AD. The first
is neurofibrillary tangle, which is present in the affected
neurons, and the second is senile plaque, which is
especially seen in the extracellular compartment of the
brain (37). The cleavage of Aβ proteins from amyloid
precursor proteins (APPs) is provided by secretases (24).
There are three proteolytic enzymes known as α-, β-, and
γ-secretases in the cleaving of APPs in neurons. The β- and
γ-secretases are thought to be related to accumulation of
Aβ proteins in neuronal cells (24).
The major pathological process related to autophagic
pathways in AD is maturation defect of autophagosomes,
which ends with massive accumulations of autophagosomes
in neurons (24,37). Because of impaired clearance of
autophagosomes which contain APPs, accumulation
gives rise to damage to neurons (38). Normally, during
autophagy, autophagosomes fuse with lysosomes and
Aβ protein-containing vacuoles are degraded within
lysosomes by hydrolysis. In AD, however, impairment
of this pathway causes an accumulation of Aβ proteins,
which become the major intracellular toxic peptides in the
neurons (24).
In the AD process, generally autophagy is stimulated to
clear the increased Aβ load, but the last step of autophagy,
which is the fusion of autophagosomes with lysosomes, is
defective, leading to massive accumulation of autophagic
vacuoles in the cytoplasm (39).
5. Animal models and studies on the relationship
between autophagy and AD
The number of studies searching for evidence about the
relationship between autophagy and AD is increasing
rapidly. A study conducted by Pickford et al. was designed
to show the effect of autophagy and deficiency of beclin-1
on the pathogenesis of AD in an animal model, and they
analyzed cortical beclin-1 protein levels of the brain in two
different lines of very old APP transgenic mice (20). They
found that beclin-1 levels were reduced early in AD in the
affected mid-frontal cortex and beclin-1 deficiency, which
disrupts neuronal autophagy, induces APP metabolism,
and causes neurodegeneration, is associated with reduced
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autophagy. This reduction is demonstrated by a decrease
in the relative levels of LC3-II compared with LC3-I. The
authors suggested that increasing beclin-1 levels might
have therapeutic potential in AD (20).
In an effort to demonstrate whether oligodendroglial
precursor cells called NG2 cells can clear β-amyloid
peptides through endocytosis and autophagy in AD, Li et
al. found that there were recruited and clustered NG2 cells
around the amyloid plaques in APPswe/PS1dE9 mice and
the NG2 cell line (40).
A recent study by Fant et al. investigated the potential
therapeutic application of leucettines, pharmacological
inhibitors of tyrosine phosphorylation regulated kinases, in
the treatment of AD, and it was found that leucettines may
trigger autophagy in immortalized mouse hippocampal
HT22 cells in this preclinical study (41). They concluded
that leucettines might activate the autophagic mTOR/
PI3K pathway and give an advantage in the treatment of
AD (41).
François et al. tried to show the link between autophagy
and inflammation in AD. They examined the inflammatory
reaction and autophagy in murine tricultures of neurons,
astrocytes, and microglia under 48-h application of various
inflammatory stresses like lipopolysaccharide and amyloid
peptide (Aβ42) (42). They found a strong relationship
between inflammation and autophagy and IL-1β played a
particularly major role in the induction of the microglial
autophagy, and they emphasized that new therapeutic
strategies in AD could target inflammation and autophagy
in microglia (42).
Zhu et al. investigated and aimed to show the therapeutic
effects of arctigenin, a natural product from Arctium
lappa, and found that arctigenin reduces Aβ production
by inhibiting the amyloid cleaving enzyme system and
induces Aβ clearance by activating the autophagic pathway
via AKT/mTOR inhibition in APP/PS1 transgenic AD
model mice (43). They also concluded that treatment with
arctigenin might decrease Aβ and senile plaque formation
and might improve memory impairment (43).
One of the major proteins in the pathogenesis of AD
is tau protein. In the animal models designed by Caccamo
et al., it was found that increased mTOR activity elevated
endogenous hyperphosphorylated tau proteins (44). They
also showed that pharmacologically reduction of mTOR
signaling with rapamycin could cause reduction in these
proteins in a mouse model (44). They concluded that
reducing the mTOR with therapeutic agents may be a
good way to treat taupathies including AD by increasing
autophagy activity in neuronal cells (44).
To show the effect of beclin-1 on autophagy, Xue et
al. examined cell viability by incubation of a medium

that contained neuron-specific enolase in PC12 cells with
elevated concentrations of Aβ for 3, 6, 12, 24, 48, and 72
h (45). They found that viability was negatively correlated
with neuron-specific enolase levels, and beclin-1 levels
decreased from 3 to 72 h (45). It was found that cell viability
was increased by rapamycin (an activator of autophagy)
but decreased by 3-methyladenine (an inhibitor of
autophagy), and they suggested that activation of beclin1-dependent autophagy before Aβ-induced cell damage
may prevent neuronal death (45).
In some studies, it was claimed that latrepirdine,
an antihistaminic agent, may affect regulation of Aβ
metabolism (46). One of these studies showed that
latrepirdine could stimulate mTOR and Atg5-dependent
autophagy, leading to reduction of Aβ protein (46). It was
also found that the biomarkers (TgCRND8) thought to
be correlated with autophagy levels increased after using
chronic latrepirdine in the mouse model (46).
Biopsy specimens of the neocortex from 7 patients
with AD and 3 non-AD control brains were analyzed using
immunoelectron microscopy in a study designed by Nixon
et al. to identify characterization of autophagosomes and
related autophagic vacuoles and to differentiate them
from other lysosome-related compartments in AD brains
and investigate the possible involvement of autophagy
in AD (47). It was found that there were accumulated
multivesicular and multilamellar bodies, autophagosomes,
and cathepsin-containing autophagolysosomes in large
numbers and they were different from lysosomes, which
were previously shown to be accumulated in dystrophic
neurites. It was concluded that impaired macroautophagy
could have a role in the pathogenesis of AD (47).
6. Conclusion
Growing
concern
about
the
knowledge
of
pathophysiological effects of autophagy in the AD
process can be seen in the literature, but studies showing
the exact relationship between AD and autophagy are
still not sufficient. The present evidence shows impaired
autophagy causing accumulation of some pathological
proteins, which lead to degeneration of neurons resulting
in neurodegenerative disorders like AD. Complex genetic
and enzymatic relationships in these mechanisms may
provide new therapeutic approaches to the treatment of
AD. It is not certain whether AD would become a curable
disease via targeting therapies in the future, but the
therapies concerning autophagic pathways are promising.
Future studies are needed in this area to improve the
clinical outcomes of AD and other neurodegenerative
disorders.
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